Confirms predictive value of Nociscan for identifying painful discs. Nociscan demonstrated a sensitivity of 100% and a specificity of 80% compared to provocative discography (PD), suggesting Nociscan provides better information to surgeons. BROOMFIELD, CO, March 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians ...

Core Viewpoint - Aclarion, Inc. has successfully closed a public offering of 5,175,000 units, raising approximately $3.0 million before expenses, to support its healthcare technology initiatives focused on chronic low back pain [1][2]. Group 1: Offering Details - Each unit in the offering consists of one share of common stock (or one pre-funded warrant) and two common warrants, with a public offering price of $0.58 per unit [1]. - The common warrants are immediately exercisable at a price of $0.58 per share and will expire five years from the date of issuance [1]. - The offering was conducted under a registration statement declared effective by the SEC on February 26, 2024, and was made only by means of a prospectus [2]. Group 2: Company Overview - Aclarion is a healthcare technology company utilizing Magnetic Resonance Spectroscopy (MRS) and proprietary algorithms to assist physicians in identifying chronic low back pain [4]. - The company's primary product, Nociscan, is a SaaS platform designed to noninvasively differentiate between painful and non-painful discs in the lumbar spine, providing critical insights for treatment optimization [4].

BROOMFIELD, CO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, today announced the pricing of its public offering of 5,175,000 units, with each unit consisting of one share of common stock (or one pre-funded warrant in lieu thereof), and two common warrants ...

Aclarion (NASDAQ:ACON) stock is falling on Monday after the healthcare technology company revealed plans for a public offering of its shares.Aclarion intends to offer up to 3,888,888 units in this offering. Each of these units will contain one share of ACON stock and a warrant to acquire another share.The finer details of the public offering still aren’t available. While the company has an assumed price of $1.80 per unit, that’s not concrete. It also hasn’t revealed the exercise price of the warrants in the ...

Exhibit 99.1 INDEX TO FINANCIAL STATEMENTS Aclarion, Inc. Page Financial Statements Report of Independent Registered Public Accounting Firm - Haynie & Company LLP (ID# 457) F-2 Report of Independent Registered Public Accounting Firm CohnReznick LLP (ID# 596) F-3 Balance Sheets at December 31, 2023 and 2022 F-4 Statements of Operations, for the Years Ended December 31, 2023 and 2022 F-5 Statements of Changes in Stockholders’ Equity (deficit), for the Years Ended December 31, 2023 and 2022 F-6 Statements of C ...

Company is initiating its pivotal multicenter, prospective, randomized CLARITY trial to build on clinical evidence demonstrating superior surgical outcomes when Nociscan is utilized in surgical decisioning 5 additional Key Opinion Leader (KOL) surgeons expected to adopt Nociscan through the Alphatec strategic partnership in 1H24 BROOMFIELD, CO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is l ...

Stock Issuance and Dilution - Aclarion issued 500,000 shares of ACON stock in exchange for $1,185,226 of principal and accrued interest on unsecured non-convertible notes, increasing the total number of outstanding shares to 1,791,375 [1] - The company may enact similar exchanges in the future to cover financing from those notes [1] - Increasing the total number of shares often results in a stock's price falling due to dilution of current investors' stakes [1] ACON Stock Performance - ACON stock is down 15.5% as of Monday morning, with about 367,000 shares traded compared to the daily average trading volume of 1.2 million shares [2] - The stock was down 14.4% year-to-date as of Friday's close [2] Market Context - The article mentions other stocks such as SoFi Technologies (NASDAQ:SOFI), Panbela Therapeutics (NASDAQ:PBLA), and Revelation Biosciences (NASDAQ:REVB) as part of the broader stock market news [2] - InvestorPlace typically avoids publishing commentary on companies with a market cap of less than $100 million or trading less than 100,000 shares daily due to the risks associated with low-volume stocks [3]

Dr. Uribe is Chief of the Division of Spinal Disorders, Volker K. H. Sonntag Chair of Spine Research, and Vice Chairman of Neurosurgery at Barrow Neurological Institute Dr. Uribe Becomes Aclarion's 3rd KOL With Access to a Diagnostic Center Authorized to Perform Nociscans BROOMFIELD, CO, Jan. 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire –  Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligenc ...

Partnership aims to include Aclarion's surgical decision support technology within ATEC's AlphaInformatiX platform to better inform spine surgery Aclarion's Nociscan is the first augmented intelligence platform to measure pain biomarkers in the lumbar spine to help physicians identify the location of chronic low back pain BROOMFIELD, CO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveragi ...

Core Viewpoint - Aclarion, Inc. will execute a 1-for-16 reverse stock split of its common stock effective January 4, 2024, to meet Nasdaq listing standards and increase its stock price above $1.00 [1][2][4] Group 1: Reverse Stock Split Details - The reverse stock split was approved by stockholders on March 24, 2023, and the Board of Directors set the ratio at 1-for-16 [2] - Post-split, the number of outstanding shares will decrease from approximately 13.4 million to about 840,000 [4] - The reverse stock split will not affect the authorized number of shares, and fractional shares will be rounded up to the nearest whole share [3][4] Group 2: Impact on Securities - The reverse stock split will also apply to outstanding warrants, stock options, and restricted stock units, with adjustments made to the number of shares and exercise prices [3] - A new CUSIP number (655187201) will be assigned to the shares, which will begin trading on a split-adjusted basis on January 4, 2024 [3] Group 3: Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, utilizing Magnetic Resonance Spectroscopy (MRS) and proprietary algorithms through its Nociscan platform [5] - Nociscan is designed to help physicians differentiate between painful and non-painful discs in the lumbar spine, providing critical insights for treatment optimization [5]